SK Labs Reveals Cancer 'Erasers' Targeting Hard-to-Treat Tumors

KING OF PRUSSIA, Pa. – April 17, 2026 – SK Life Science Labs, a subsidiary of the global biotech firm SK Biopharmaceuticals, today announced it will present promising new preclinical data for a novel class of cancer drugs at the American Association for Cancer Research (AACR) Annual Meeting. The findings, set to be unveiled in San Diego, showcase a new generation of therapies known as targeted protein degraders, which have demonstrated potent anti-tumor activity against key drivers in prostate cancer, multiple myeloma, and other challenging malignancies.

The company will present data from three posters on its selective p300 and PRMT5 degrader programs. These therapies represent a significant leap beyond traditional cancer treatments, designed not merely to inhibit harmful proteins but to mark them for complete destruction by the body’s own cellular machinery. The advancement places the Pennsylvania-based lab at the forefront of one of oncology's most exciting frontiers and signals a major strategic push by its parent company into next-generation cancer therapeutics.

A New Era: Erasing Cancer Proteins, Not Just Blocking Them

For decades, the cornerstone of targeted cancer therapy has been inhibition—developing small molecules that fit into the active sites of oncogenic proteins like a key in a lock, blocking their function. While this approach has led to numerous life-saving drugs, it has inherent limitations, including the development of drug resistance and the inability to target the roughly 85% of human proteins that lack such a "druggable" pocket.

Targeted protein degradation (TPD) offers a revolutionary alternative. Instead of just blocking a protein, degraders hijack the cell's natural disposal system, the ubiquitin-proteasome system (UPS), to physically eliminate the target protein entirely. These sophisticated molecules act as a bridge, linking a disease-causing protein to an E3 ligase, an enzyme that tags the unwanted protein for destruction by the proteasome, the cell's "garbage disposal."

This "erase, don't block" strategy carries profound advantages. It can neutralize proteins regardless of whether they have an active site, opening up a vast new landscape of previously "undruggable" targets. Because the degrader molecule acts catalytically—meaning one molecule can trigger the destruction of many protein targets before moving on—they can be effective at very low doses, potentially reducing side effects. This approach can also overcome common resistance mechanisms, as it’s much harder for a cancer cell to adapt to the complete absence of a protein it depends on for survival.

"Our latest findings further demonstrate the power of targeted protein degradation to selectively eliminate key cancer vulnerabilities with depth and precision that may not be achievable with traditional inhibition," said Ryan Kruger, Ph.D., Chief Scientific Officer at SK Life Science Labs, in a statement.

Targeting Key Vulnerabilities: p300 and PRMT5

SK Life Science Labs is applying this cutting-edge science to two high-value oncology targets: p300 and PRMT5. Both are master regulators of gene expression that, when dysregulated, play central roles in the growth and survival of multiple cancers.

The company’s p300 degrader program is particularly noteworthy for its dual-pronged attack. One set of data highlights "deep anti-tumor activity" in cancers with mutations in the CBP gene. Because p300 and CBP are closely related proteins, cancers that lose CBP function often become critically dependent on p300 for survival—a concept known as synthetic lethality. By selectively destroying p300, the degrader pulls the rug out from under these tumor cells, causing them to collapse.

A second presentation will show the degrader’s broad efficacy in p300-dependent cancers, specifically showing robust activity in preclinical models of prostate cancer and multiple myeloma. This could provide a much-needed new therapeutic option for patients with these common and often difficult-to-treat diseases. The company emphasizes the high selectivity of its p300 degraders, which may help avoid toxicities associated with less precise dual p300/CBP inhibition.

The third pillar of the AACR presentation is a next-generation PRMT5 degrader. PRMT5 is a well-established cancer target implicated in numerous solid tumors and blood cancers, and several companies are developing traditional PRMT5 inhibitors. However, SK Life Science Labs is betting that degradation offers a superior path. By eliminating the entire PRMT5 protein, their approach aims to shut down both its catalytic and non-catalytic functions, some of which may not be addressed by inhibitors. This could lead to a more profound and durable anti-tumor effect and potentially overcome the limitations and resistance pathways that have challenged first- and second-generation PRMT5 inhibitors.

A Strategic Play in a Competitive Field

The move into targeted protein degradation is a clear strategic imperative for SK Biopharmaceuticals and its parent, the South Korean conglomerate SK Group. The field is one of the hottest areas in biopharma, with pioneers like Arvinas and Kymera Therapeutics already advancing degraders through human clinical trials and attracting multi-billion dollar partnerships.

SK Life Science Labs, formerly Proteovant Therapeutics, is positioning itself to be a major contender. The announcement that its p300 degrader program is already "progressing through IND-enabling studies" is a significant indicator of its maturity. This is the final and rigorous stage of preclinical research required before a company can apply to the FDA to begin clinical trials in humans, suggesting the program is on a clear path toward the clinic.

The company's scientific engine, which combines AI-driven target identification with a proprietary "MOPED™" molecular glue screening platform, provides a powerful and versatile discovery toolkit. This dual capability in both traditional PROTAC-style degraders and the more recently appreciated "molecular glues" gives the lab a competitive edge in tackling a wider array of challenging targets.

Backed by the deep pockets and long-term vision of the SK Group, which was named one of TIME's 100 Most Influential Companies, SK Life Science Labs has the resources to pursue this capital-intensive, high-risk, high-reward area of drug development. The data presented at AACR 2026 will be a critical test, offering the first public glimpse into whether this strategic investment is poised to pay off and deliver a new class of powerful medicines for cancer patients.